Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
August 07, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2018 financial results and described recent clinical and...
Immuron Announces it has Received a European Patent Grant for NASH treatment
July 24, 2018 06:30 ET
|
Immuron Limited
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally...
Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist
June 13, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 13, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
June 06, 2018 23:14 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Metacrine Completes $65 Million Series C Financing
June 06, 2018 07:30 ET
|
Metacrine
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 05, 2018 16:10 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Metacrine to Present Role of FXR in Treating Inflammatory Bowel Disease at Digestive Disease Week 2018
May 31, 2018 16:05 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Metacrine to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 07:30 ET
|
Metacrine
SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Metacrine, Inc., an innovative biotechnology company developing therapies to benefit patients with liver, gastrointestinal and metabolic diseases, today...
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
May 31, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy -- -- Statistically...
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
May 08, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results. During the first quarter, the Company...